The JTB Knockout NCI-H1975 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population specifically engineered to disrupt the JTB gene in the NCI-H1975 human lung adenocarcinoma cell line. This polyclonal format provides a heterogeneous cell pool with targeted gene disruptions, supporting reproducible loss-of-function studies in apoptosis and cancer biology. The use of a polyclonal population avoids clonal artifacts and better represents the cellular diversity found in tumor microenvironments.
The NCI-H1975 cell line was established from the pleural effusion of a nonsmoking female patient with non-small cell lung adenocarcinoma. It serves as a well-characterized model for EGFR-mutant NSCLC, retaining an EGFR exon 21 L858R mutation. Widely employed to investigate EGFR signaling, drug resistance mechanisms, and tumor cell biology, NCI-H1975 cells offer a clinically relevant platform for lung cancer research.
JTB (Jumping Translocation Breakpoint) encodes a mitochondrial outer membrane protein with pivotal roles in apoptosis regulation, mitochondrial dynamics, and cell cycle progression. Mechanistically, JTB facilitates BAX oligomerization and cytochrome c release from mitochondria, thereby activating caspase-9 and caspase-3 to execute programmed cell death. JTB interacts with BCL2, VDAC, and mitochondrial import receptors, and its downstream targets??BCL2, BAX, and cytochrome c??are essential components of the intrinsic apoptotic pathway.
In the NCI-H1975 cellular context, JTB knockout is expected to impair intrinsic apoptotic signaling, potentially enhancing cell survival and resistance to genotoxic agents used in cancer therapy. Given the role of apoptosis evasion in EGFR-mutant NSCLC, this model provides a tool for dissecting apoptosis resistance mechanisms and uncovering mitochondrial dysfunction-driven drug resistance. The disruption of JTB-mediated mitochondrial apoptosis pathways may promote pro-survival signaling, making these cells valuable for studying vulnerabilities in lung cancer cell maintenance and therapeutic response.
These JTB knockout polyclonal cells enable a broad range of experimental applications. Apoptotic function can be assessed via Annexin V/PI staining, JC-1-based mitochondrial membrane potential measurements, and caspase-3/7 activity assays. Western blotting for BCL2 family proteins (including BCL2 and BAX) and cytochrome c release assays allow interrogation of pathway alterations following JTB disruption. MTT cell viability assays support drug response profiling, particularly for agents targeting the mitochondrial apoptosis axis. The model is suitable for investigating mitochondrial dysfunction, cancer cell survival signaling, and apoptosis resistance in non-small cell lung carcinoma. For technical inquiries or to order, please contact Ascent Research.
